Feb. 15 at 6:51 AM
$MCRB Q2 2026 Data: Despite pausing the Phase 2 trial, initial results from a smaller, investigator-sponsored study of SER-155 in immune checkpoint-related enterocolitis (irEC) are still expected in early Q2 2026.
$EKSO January 2026 Private Placement: The company raised approximately
$5.9 million (
$5.3M net) through the sale of Series B preferred stock and warrants. These warrants are exercisable at
$8.22 per share starting in July 2026.
$KPLT Earnings Beat: In its last reported quarter (Q3 2025), Katapult reported an EPS of -
$0.18, beating analyst estimates of -
$0.21.
Revenue Growth: Revenue was
$74.0 million, up roughly 23% year-over-year.
